|Bid||322.00 x 100|
|Ask||330.00 x 100|
|Day's Range||321.11 - 332.00|
|52 Week Range||244.28 - 348.84|
|PE Ratio (TTM)||19.88|
|Earnings Date||Feb 28, 2018 - Mar 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||358.42|
Biogen and Ionis sank after AveXis said it would start trials for a new spinal muscular atrophy treatment.
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
All the noise from Bitcoin may obscure new potential buy signals from big names like Microsoft, Intel, Fiat Chrysler, Biogen and AbbVie.
Biogen Inc. announced today that it will present at the Guggenheim 5th Annual Healthcare Conference. The webcast will be live on Wednesday, December 13, 2017 at 12:00 p.m.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Biogen, Inc. a score of 88. Our analysis is based on comparing Biogen, Inc. with the following peers – Amgen Inc., Celgene Corporation, Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Pfizer Inc., Sanofi Sponsored ADR, Acorda Therapeutics, Inc., Sangamo Therapeutics, Inc. and Bio-Rad Laboratories, Inc. Class ... Read more (Read more...)
Michael Gilman, a former Biogen executive known for launching successful biotech startups, has pulled back the curtain on his latest project: a cancer drug developer backed by $49.5 million in financing from GV, Atlas Venture and others. Cambridge-based Obsidian Therapeutics came out of stealth mode on Wednesday, saying that it hopes to create an improved class of cell and gene therapies — so-called “living” drugs that reprogram a person’s immune cells to attack tumors. Obsidian was founded in 2015 by Atlas, which exclusively funded the company’s operations through mid-2017.
Mark Hernon, a former regional IT chief at Takeda Pharmaceuticals, will oversee innovative IT tools that help develop treatments for Alzheimer’s, dementia and other neurological diseases, the biotech firm ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biogen, Inc. Here are 5 ETFs with the largest exposure to BIIB-US. Comparing the performance and risk of Biogen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Biogen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Sarissa Capital Management last week made nearly $15 million in stock purchases. Sarissa, a hedge fund that specializes in drug developers, added to positions in Biogen (BIIB) and Medicines (MDCO). On Nov. 28 and 29 the fund bought 30,000 shares of Biogen for $9.52 million, or $317.36 each.
Biogen announced today the appointment of Mark Hernon as Senior Vice President, Chief Information Officer, effective December 4.
The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.
While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.
NEW YORK, Nov. 29, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aflac ...
Shares of Biogen (BIIB) and Alkermes (ALKS) are both higher on Tuesday, after they announced a licensing agreement to develop and commercialize ALKS 8700, a multiple sclerosis treatment. The drug, which ...
NEW YORK, NY / ACCESSWIRE / November 28, 2017 / Israeli-based Teva (NYSE: TEVA) saw big gains on Monday after the company announced it would be revealing a detailed restructuring plan next month. This ...
Biogen will pay Alkermes up to $228 million to gain another multiple sclerosis asset as key drug Tecfidera faces a patent cliff in the mid-2020s.